Evaxion Biotech A/S (NASDAQ: EVAX) a clinical-stage biotechnology company focused on the creation of AI-driven immunotherapies, announced today that it has chosen EVX-03 as the product candidate within its DNA technology platform to target a new indication with a planned regulatory filing in H2 2022. Our DNA technology platform currently has the product candidates EVX-02 and EVX-03. We have chosen to use EVX-03 in an upcoming clinical trial for a novel indication in light of the highly favorable outcomes from our pre-clinical tests of this candidate.
Enhanced DNA technology in EVX-03APC-targeting unit (Antigen-Presenting Cell) in ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
Evaxion Biotech Broadens EVX-03 DNA Vaccine Project Into Non-Small Cell Lung Cancer.